Skip to main content Accessibility help
×
Home
  • Print publication year: 2012
  • Online publication date: July 2012

Chapter 70 - Treatment with ‘new’ antiepileptic drugs

from Section 5 - Management of epilepsy

References

Chadwick DW, Marson T, Kadir Z. Clinical administration of new antiepileptic drugs: an overview of safety and efficacy. Epilepsia 1996;37(Suppl 6):S17–22.
Luciano AL, Shorvon SD. Results of treatment changes in patients with apparently drug-resistant chronic epilepsy. Ann Neurol 2007;62(4):375–81.
Marson AG, Al-Kharusi AM, Alwaidh M, et al.; SANAD Study group. The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial. Lancet 2007a;369(9566):1016–26.
Marson AG, Al-Kharusi AM, Alwaidh M, et al.; SANAD Study group. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblended randomised controlled trial. Lancet 2007b;369(9566):1000–15.
Mohanraj R, Brodie MJ. Diagnosing refractory epilepsy: response to sequential treatment schedules. Eur J Neurol 2006;13(3):277–82.
National Institute for Health and Clinical Excellence. Newer Drugs for Epilepsy in Adults. NICE Technology Appraisal Guidance no. 76. London: National Institute for Health and Clinical Excellence; 2004. Available from: http://www.nice.org.uk/TA076.